Sinopharm, the biologics arm of CNBG, partnered with ImmunoBiology (ImmBio), a Cambridge UK vaccine company, to co-develop ImmBio's novel PnuBioVax vaccine against pneumonia and will be in charge of China commercialization. Sinopharm, which will make ...

Featured Events

May 8-9, 2019
Shanghai, China
Take advanage of the early bird discount before March 31, 2019.
 

ChinaBio® Daily Update

Contents


Sinopharm Partners with ImmBio on Broad-Spectrum Pneumonia Vaccine

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Sinopharm, the biologics arm of CNBG, partnered with ImmunoBiology (ImmBio), a Cambridge UK vaccine company, to co-develop ImmBio’s novel PnuBioVax vaccine against pneumonia and will be in charge of China commercialization. Sinopharm, which will make multi-million dollar milestone and royalty payments to ImmBio, will manufacture the vaccine for global use. PnuBioVax is designed to be effective against all of the 97 serotypes of the S. pneumoniae bacteria, while present vaccines target between 10 and 23 serotypes. More details....

Share this with colleagues:

     
 

Xynomic Extends Phase III Abexinostat Trial to China and Europe

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Xynomic, a US-Shanghai oncology pharma, announced that China, Spain and Poland authorities have approved Phase III trials of Xynomic's abexinostat, in combination with pazopanib, in patients with renal cell carcinoma (RCC). Abexinostat is a novel HDAC inhibitor. Xynomic has already started the same trial in the US and South Korea. Xynomic in-licensed the drug in 2017 (see story), but did not disclose details of the transaction. The molecule was developed by Pharmacyclics, which was acquired by AbbVie in 2015. More details....

Share this with colleagues:

     
 

Week in Review: Inventis Closes $70 Million Financing to Develop 30 Novel Therapeutics

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Deals and Financings

• InventisBio of Shanghai closed a $70 million Series C financing to develop its portfolio of 30 novel therapeutics for cancer and metabolic diseases;
• BGI Genomics of Shenzhen formed a $50 million partnership with Natera to commercialize Natera's Signatera™ MRD (minimal residual disease) test in China;
• Shanghai's Newsoara acquired Asia rights to develop a TaiwanJ treatment for nonalcoholic steatohepatitis (NASH) in a $26 million agreement;
• Shanghai Changren Information Technology, a China IT health management company, raised $15 million in a Series A funding round;
• Yunhu Technology of Hangzhou secured "tens of millions RMB" in a Series A+ financing company for its China primary medical services internet platform;
• Chengdu's HitGen will collaborate with Sun Pharma Advanced Research Company of India to discover small molecule leads;
• CASI, a US-Beijing pharma, out-licensed China marketing rights for Evomela® (melphalan hydrochloride for injection) in China to CR Guokang;

Company News

• Dr. Zhengqing Li became Ascletis' CMO and President of R&D Greater China after eight years as General Manager of MSD's R&D Center China;

Trials and Approvals

• CStone Pharma (Suzhou) was approved to start a China Phase I trial of its histone deacetylase 6 (HDAC6) selective inhibitor;
• CARsgen, a Shanghai biopharma, was approved to start China clinical trials of its fully human BCMA CAR-T cell therapy in patients with multiple myeloma.

Stock Symbols: (SHZ: 300696) (NSDQ: NTRA) (BSE: 532872) (NSDQ: CASI) (HK: 2616)

Share this with colleagues:

     
 

Yunhu Completes A+ Round for Internet-based China Primary Medical Care

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Yunhu Technology, a Hangzhou company that offers an internet platform for China primary medical services, has secured "tens of millions RMB" in a Series A+ financing. Founded in 2017, Yunhu claims to be China's first internet platform for medical examination that connects with over a thousand local medical institutions. The A+ round was led by China Creation Ventures and joined by existing backers including Vision+ Capital, Morningside Venture Capital, Cash Capital and BioTrack Capital. More details....

Share this with colleagues:

     
 

Shanghai Changren Completes $15 Million Round for IT Health Management

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai Changren Information Technology, a China IT health management company, raised $15 million in a Series A funding round led by an unnamed state-owned enterprise, according to press reports. Founded in 2016, Changren provides health management services for individuals and institutions based on its whole life cycle dynamic physiological big data. The company's major product, a home medical robot called "Xiaobao," takes a patient's vital signs at home, transmits them to a cloud platform, and provides medical guidance (medication, diet, and exercise recommendations) through voice broadcasts or short videos. More details....

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


 


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy